Cai Jiang

Dr. Cai Jiang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JHJinnan Hu
Jinnan Hu
CJCai Jiang
Cai Jiang
YHYu S. Huang
Yu S. Huang
HCHaodong Chen
Haodong Chen
HFHanying Feng
Hanying Feng
WCWeizhi Chen
Weizhi Chen
Liquid biopsy enables identification of low allele frequency (AF) tumor variants and novel clinical applications such as minimum residual disease (MRD) monitoring. However, challenges remain, primarily due to limited sample volume and low read count of low-AF variants. Because of the low AFs, some clinically significant variants are difficult to distinguish from errors introduced by PCR amplification and sequencing. Unique Molecular Identifiers (UMIs) have been developed to further reduce base error rates and improve the variant calling accuracy, which enables better discrimination between background errors and real somatic variants. While multiple UMI-aware ctDNA analysis pipelines have been published and adopted, their accuracy and runtime efficiency could be improved. In this study, we present the Sentieon ctDNA pipeline, a fast and accurate solution for small somatic variant calling from ctDNA sequencing data. The pipeline consists of four core modules: alignment, consensus generation, variant calling, and variant filtering. We benchmarked the ctDNA pipeline using both simulated and real datasets, and found that the Sentieon ctDNA pipeline is more accurate than alternatives.

16 March 2023 in Molecular Oncology
Verified
Journal Article
Open access
BWBing Wei
Bing Wei
JZJinxiang Zheng
Jinxiang Zheng
CJCai Jiang
Cai Jiang
HZHe Zhang
He Zhang
MZMingye Zhang
Mingye Zhang
JMJie Ma
Jie Ma
As homologous recombination deficiency (HRD) is a biomarker to predict the efficiency of PARP inhibitor treatment, this study developed a non-exonic single-nucleotide polymorphism (SNP)-based targeted next-generation sequencing panel and comprehensively examined it both on standard and clinical ovarian cancer tissues. The HRD scores calculated by the panel and whole-genome sequencing were consistent, with the analysis by sequenza being the most reliable. The results on clinical samples revealed that the panel performed better in HRD analysis compared with the SNP microarray. There are several distinctions between this newly developed kit and reported HRD detection panels. First, the panel covers only 52 592 SNPs, which makes it capable of detecting genomic instability. Secondly, all the SNPs are non-exonic; as a result, the panel can be used cooperatively with any exon panel. Thirdly, all the SNPs selected have a high minor allele frequency in Chinese people, making it a better choice for HRD detection in Chinese patients. In summary, this panel shows promise as a clinical application to guide PARP inhibitors or platinum drugs used in the treatment of ovarian and other cancers.

1 January 2026 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
ZWZhizhong Wang
Zhizhong Wang
XYXinXin Yang
XinXin Yang
TCTaoran Cheng
Taoran Cheng
JFJunnan Feng
Junnan Feng
JZJinxiang Zheng
Jinxiang Zheng
BWBing Wei
Bing Wei
Wang Z, et al. J Gynecol Oncol. 2026 ;37:e97. https://doi.org/10.3802/jgo.2026.37.e97